The Global Mantle Cell Lymphoma Market is projected to expand from USD 2.71 Billion in 2025 to USD 4.28 Billion by 2031, registering a CAGR of 7.91%. This rare and aggressive B-cell malignancy, marked by cyclin D1 overexpression, is seeing increased demand for therapeutics due to the rising prevalence of hematologic cancers in aging populations and the regulatory success of targeted oral drugs and immunotherapies. These structural drivers provide a solid foundation for long-term industry growth that remains distinct from fleeting market trends or temporary prescribing shifts.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 2.71 Billion
Market Size 2031	USD 4.28 Billion
CAGR 2026-2031	7.91%
Fastest Growing Segment	Surgical Examination
Largest Market	North America

However, the sector faces significant obstacles regarding the high acquisition costs of advanced treatments, which limit widespread patient access and reimbursement coverage. This financial strain places severe pressure on healthcare systems and restricts market penetration in cost-sensitive regions. To illustrate the scale of the disease burden, the American Cancer Society estimated that approximately 80,350 new cases of non-Hodgkin lymphoma would occur in the United States in 2025, with Mantle Cell Lymphoma representing a critical and aggressive subset of this total.

Market Driver

The rapid approval of novel targeted therapies, particularly Bruton tyrosine kinase inhibitors, serves as a primary catalyst for market growth by shifting the treatment paradigm away from traditional cytotoxic chemotherapy. This transition is supported by clinical trials demonstrating superior safety and progression-free survival in both frontline and relapsed settings. For example, AstraZeneca reported in June 2024 that the ECHO trial showed acalabrutinib reduced the risk of disease progression or death by 27% compared to standard care, encouraging healthcare providers to adopt these premium-priced oral therapies earlier in the treatment continuum.

Simultaneously, the growing adoption of CAR-T cell therapies and immunotherapies is addressing high unmet needs for patients with refractory disease who have exhausted other options. These distinct biological treatments offer durable remission possibilities, sustaining market value through their high reimbursement potential. According to Gilead Sciences' third-quarter 2024 financial results, sales of the cell therapy Tecartus totaled $98 million, highlighting significant adoption despite the niche patient population, which the Lymphoma Research Foundation noted in 2024 accounts for roughly 6% of all non-Hodgkin lymphoma cases.

Market Challenge

The primary barrier hampering the Global Mantle Cell Lymphoma Market is the prohibitive cost associated with novel therapeutic modalities. Advanced treatments, such as CAR-T cell therapies and continuous oral kinase inhibitors, carry substantial price tags that frequently exceed the budgetary limits of public and private payers. This financial toxicity necessitates strict utilization management and rigorous reimbursement criteria, which directly restricts patient access to these potentially life-extending regimens and dampens overall revenue expansion in cost-sensitive regions.

This economic friction is further intensified by the orphan nature of the disease, which compels manufacturers to maintain high per-patient pricing to recover development costs from a limited population. The constrained volume of the target market makes the industry highly sensitive to access limitations. As reported by the American Society of Hematology, the annual incidence of Mantle Cell Lymphoma in the United States was projected to reach approximately 3,589 cases in 2025. This small patient pool, coupled with high treatment costs, forces a selective approach to prescribing that impedes the broader commercial trajectory of innovative therapies.

Market Trends

The widespread adoption of non-covalent BTK inhibitors is systematically addressing the therapeutic void left by covalent resistance mechanisms, particularly for patients whose disease progresses on standard frontline agents. By utilizing a reversible binding mode, novel therapies such as pirtobrutinib effectively re-establish disease control in tumors harboring mutations that render traditional irreversible inhibitors ineffective. This clinical utility is driving substantial market traction; Eli Lilly reported in October 2024 that third-quarter revenue for the non-covalent inhibitor Jaypirca reached $81 million, reflecting its rapid integration into treatment protocols for relapsed cases.

Concurrently, the emergence of bispecific antibodies acts as a disruptive force by providing immediate, off-the-shelf immunotherapeutic options that rival the efficacy of cell-based therapies. These agents bypass the manufacturing delays and logistical complexities of autologous CAR-T cells by engaging endogenous T-cells to directly target tumor antigens, making them highly suitable for patients with rapidly progressing disease. Underscoring the high efficacy of this approach, OncLive reported in December 2024 that study results presented at the 2024 ASH Annual Meeting demonstrated that glofitamab monotherapy elicited an overall response rate of 82% in the relapsed/refractory setting.

Key Market Players

Gilead Sciences, Inc.
F. Hoffman La Roche Ltd
Abbvie, Inc.
Celgene Corporation
Eli Lilly and Company
Amgen, Inc.
Takeda Pharmaceutical Co. Ltd
AstraZeneca Plc
Johnson and Johnson Services Inc.
BeiGene GmBH

Report Scope

In this report, the Global Mantle Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mantle Cell Lymphoma Market, By Diagnosis

Laboratory exams
Imaging Tests
Bone marrow Biopsy
Others

Mantle Cell Lymphoma Market, By Treatment

Diagnosis {Imaging Tests, Surgical Examination, Others}
Therapy {Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others}

Mantle Cell Lymphoma Market, By End User

Hospitals & Clinics
Ambulatory Care Centers
Others

Mantle Cell Lymphoma Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mantle Cell Lymphoma Market.

Available Customizations:

Global Mantle Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mantle Cell Lymphoma Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Diagnosis (Laboratory exams, Imaging Tests, Bone marrow Biopsy, Others)
- 5.2.2. By Treatment (Diagnosis {Imaging Tests, Surgical Examination, Others}, Therapy{Chemotherapy, Targeted therapy, Immunotherapy, Stem Cell Transplantation, Others)
- 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Mantle Cell Lymphoma Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Diagnosis
- 6.2.2. By Treatment
- 6.2.3. By End User
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Mantle Cell Lymphoma Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Diagnosis
    - 6.3.1.2.2. By Treatment
    - 6.3.1.2.3. By End User
- 6.3.2. Canada Mantle Cell Lymphoma Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Diagnosis
    - 6.3.2.2.2. By Treatment
    - 6.3.2.2.3. By End User
- 6.3.3. Mexico Mantle Cell Lymphoma Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Diagnosis
    - 6.3.3.2.2. By Treatment
    - 6.3.3.2.3. By End User

7. Europe Mantle Cell Lymphoma Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Diagnosis
- 7.2.2. By Treatment
- 7.2.3. By End User
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Mantle Cell Lymphoma Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Diagnosis
    - 7.3.1.2.2. By Treatment
    - 7.3.1.2.3. By End User
- 7.3.2. France Mantle Cell Lymphoma Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Diagnosis
    - 7.3.2.2.2. By Treatment
    - 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Mantle Cell Lymphoma Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Diagnosis
    - 7.3.3.2.2. By Treatment
    - 7.3.3.2.3. By End User
- 7.3.4. Italy Mantle Cell Lymphoma Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Diagnosis
    - 7.3.4.2.2. By Treatment
    - 7.3.4.2.3. By End User
- 7.3.5. Spain Mantle Cell Lymphoma Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Diagnosis
    - 7.3.5.2.2. By Treatment
    - 7.3.5.2.3. By End User

8. Asia Pacific Mantle Cell Lymphoma Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Diagnosis
- 8.2.2. By Treatment
- 8.2.3. By End User
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Mantle Cell Lymphoma Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Diagnosis
    - 8.3.1.2.2. By Treatment
    - 8.3.1.2.3. By End User
- 8.3.2. India Mantle Cell Lymphoma Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Diagnosis
    - 8.3.2.2.2. By Treatment
    - 8.3.2.2.3. By End User
- 8.3.3. Japan Mantle Cell Lymphoma Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Diagnosis
    - 8.3.3.2.2. By Treatment
    - 8.3.3.2.3. By End User
- 8.3.4. South Korea Mantle Cell Lymphoma Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Diagnosis
    - 8.3.4.2.2. By Treatment
    - 8.3.4.2.3. By End User
- 8.3.5. Australia Mantle Cell Lymphoma Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Diagnosis
    - 8.3.5.2.2. By Treatment
    - 8.3.5.2.3. By End User

9. Middle East & Africa Mantle Cell Lymphoma Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Diagnosis
- 9.2.2. By Treatment
- 9.2.3. By End User
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Mantle Cell Lymphoma Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Diagnosis
    - 9.3.1.2.2. By Treatment
    - 9.3.1.2.3. By End User
- 9.3.2. UAE Mantle Cell Lymphoma Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Diagnosis
    - 9.3.2.2.2. By Treatment
    - 9.3.2.2.3. By End User
- 9.3.3. South Africa Mantle Cell Lymphoma Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Diagnosis
    - 9.3.3.2.2. By Treatment
    - 9.3.3.2.3. By End User

10. South America Mantle Cell Lymphoma Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Diagnosis
- 10.2.2. By Treatment
- 10.2.3. By End User
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Mantle Cell Lymphoma Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Diagnosis
    - 10.3.1.2.2. By Treatment
    - 10.3.1.2.3. By End User
- 10.3.2. Colombia Mantle Cell Lymphoma Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Diagnosis
    - 10.3.2.2.2. By Treatment
    - 10.3.2.2.3. By End User
- 10.3.3. Argentina Mantle Cell Lymphoma Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Diagnosis
    - 10.3.3.2.2. By Treatment
    - 10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Mantle Cell Lymphoma Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Gilead Sciences, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. F. Hoffman La Roche Ltd
15.3. Abbvie, Inc.
15.4. Celgene Corporation
15.5. Eli Lilly and Company
15.6. Amgen, Inc.
15.7. Takeda Pharmaceutical Co. Ltd
15.8. AstraZeneca Plc
15.9. Johnson and Johnson Services Inc.
15.10. BeiGene GmBH

16. Strategic Recommendations

17. About Us & Disclaimer

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ

SELECT AN OPTION